Immunochemistry diagnostic devices market seen reaching $6.22 billion by 2030

The global immunochemistry diagnostic devices and equipment market is projected to grow from $3.67 billion in 2025 to $6.22 billion by 2030 as demand rises for precision diagnostics, automation and personalized medicine. North America led the market in 2025, with Asia-Pacific in second place.

Why it matters: - The market sits at the center of faster diagnosis, more targeted treatment and broader use of automated lab systems. - Growth in immunochemistry devices can affect how hospitals and labs detect cancer markers, hormone levels and infectious diseases. - The segment’s expansion also tracks with the shift toward personalized medicine, which depends on biomarker testing to guide treatment choices.

What happened: - The Business Research Company released a market intelligence report on the global immunochemistry diagnostic devices and equipment market. - The market is estimated at $3.67 billion in 2025 and is projected to rise to $4.11 billion in 2026. - The report forecasts the market will reach $6.22 billion by 2030. - The report covers regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - Download a free sample of the report - View the full market report

The details: - The market’s historical growth has been driven by higher clinical diagnostic testing volumes and rising rates of chronic and infectious diseases. - Expansion of centralized diagnostic labs has added to demand. - Wider use of immunoassays in oncology and endocrinology has supported market growth. - Improvements in laboratory infrastructure have also contributed. - The forecast assumes a 10.9% CAGR from 2026 to 2030. - The report points to rising demand for precision diagnostics, broader adoption of automated laboratory systems and more investment in advanced diagnostic technologies. - The report also highlights early disease detection as a growth driver. - Expected trends include more automated immunoassay analyzers, higher demand for sensitive diagnostic reagents, broader use of multiplex testing platforms, more lab automation and greater focus on workflow efficiency and accuracy. - Immunochemistry diagnostic devices and equipment are medical tools that detect and quantify substances such as proteins and hormones through immune reactions. - These systems are used for hormone assays, cancer marker detection and infectious disease diagnostics. - The tools are widely used in laboratories and healthcare settings to support accurate and efficient testing. - Personalized medicine is a major catalyst because it relies on immunochemistry assays to identify biomarkers that support tailored treatment plans. - In February 2024, the Personalized Medicine Coalition reported that 20 of 53 new therapeutic molecular entities approved by the FDA in 2023 were classified as personalized medicines. - The coalition also said six new gene and cell-based therapies were approved, together representing roughly 38% of all new molecular entities authorized in the United States. - North America was the largest regional market in 2025. - Asia-Pacific ranked second in 2025.

Between the lines: - The market’s growth profile suggests diagnostics companies are benefiting from two forces at once: more testing volume and more complex testing needs. - Automation and multiplex testing point to pressure on labs to do more with fewer resources while maintaining accuracy. - Personalized medicine is likely to keep pushing demand for biomarker-based assays as treatment becomes more individualized.

What’s next: - The report expects continued expansion through 2030 as precision diagnostics and automated lab workflows gain wider adoption. - The company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated graphics and tables. - The market will likely be shaped by laboratories investing in speed, sensitivity and efficiency.

The bottom line: - Immunochemistry diagnostic devices and equipment are moving from a steady-growth category to a core piece of precision medicine infrastructure.